Investing.comDoubao · 实盘不做把握 7/10不做原因:无可交易标的
北京时间·🕒 发布 19:32:43·⟳ 抓取 19:33:39 +56s·⚡ 决策 10-21 19:45:26 +11m47s·6.3 天前
Bodycote 股东以99.79%批准 Veritas Capital 现金收购，HSR 等待期已过，仍待多国反垄断/FDI审批及法院批准（注：正文抬头的 SpaceX/Tesla 标题系 AI 生成串文，与本事件无关）
这是一笔英国上市公司的现金 scheme of arrangement，标的 Bodycote 仅在伦交所上市且无 ADR，不在可交易市场；买方为非上市私募基金。且本次只是自9月1日已公告、9月28日已发 scheme document 后预期内的股东投票程序性落地（99.79%赞成毫无悬念），唯一可博弈的是套利利差（承担多国监管与法院审批、约一个季度的时间成本及交易破裂风险），既无方向性催化也无可执行交易载体，故回避。
📄 原文Investing.com↗ 原文
Bodycote shareholders approve Veritas Capital acquisition
SpaceX, Tesla shares rise after Musk says committees exploring possible merger LONDON - Bodycote plc shareholders appro…
不做 Bodycote plc（BOY.GB）
无可交易载体（仅伦交所上市、无美国ADR，不在本臂市场）且本次为预期内的股东投票程序性落地，自9月公告起已被定价；剩余仅为并购套利利差，需承担多国监管/法院审批与约一个季度时间及 deal-break 风险，无方向性 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Bodycote 股东高票批准 Veritas 现金收购属并购流程中预期内的程序性里程碑，交易条款9月初已公开并被定价；公司仅在伦交所上市、无可交易 ADR，买方为私募，剩余仅是套利利差对监管/时间风险，无方向性 edge 且无合适可交易标的。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 medium · price-in 风险 high ↗
消息传播链
- 报道称当日上午 Court Meeting/General Meeting 高票通过收购，HSR 等待期已过，仍待多国审批与法院批准；该稿为 AI 生成、编辑审核，未核验到公司 RNS 原始公告链接。
关键理由
- 股东批准是 scheme of arrangement 既定步骤且赞成率高达99.79%，对市场不构成新增惊喜，套利利差已自9月公告起被压缩
- 唯一标的 BOY.L 在伦交所、无美股 ADR，本臂无成交载体；买方 Veritas 未上市，无法表达方向
主要风险
- 其他司法辖区并购控制/FDI审批若被否决或附加苛刻条件，存在 deal break 导致股价回落至交易前水平的风险
- 正文抬头误植 SpaceX/Tesla 合并标题，系该 AI 生成稿的串文，若被机器误关联可能造成错误标的与误判
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-21 · 影响 invalidates
交易仍待多国并购控制与FDI审批及法院批准，预计2027Q1才生效；当前收益仅为压缩后的套利利差，需承担监管否决/破裂与时间成本，无正期望方向收益。
检索:Bodycote Veritas offer price spread deal completion risk regulatory FDI approval 原文 ↗ - 做多前查反向 · 来源 web · 影响 invalidates
未发现 Bodycote 在美国的 ADR 或上市证券，Nasdaq/TipRanks 页面仅为英国股票 GB:BOY 的资讯转引，无可执行美股载体。
检索:Bodycote ADR US listing OTC tradable 原文 ↗
先例如何影响了这次决策
对本次决策的影响:强化了‘预期内程序性落地 + 无可交易载体 → 回避’的结论，未产生任何 ENTER 腿
方向:无可供本臂交易的对齐先例：英国 scheme of arrangement 现金收购的目标公司在股东通过日通常已贴近要约价，剩余收益为套利利差而非方向性涨幅
涨幅量级:无同市场（伦交所）、同机制且首发锚干净并在本臂可交易范围内的先例样本，不足以也无需校准 tp/sl
形态:程序性股东批准在现金方案中普遍为高票通过、价格反应温和（预期内事件），不构成方向性交易依据
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 3,759 ms
{"result": "search_processed_events:agent query=`bodycote veritas capital acquisition shareholder approval | bodycote vulcan alpha bidco scheme of arrangement vote | bodycote 股东批准 veritas 现金收购`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、22409 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重 - web_search 成功 doubao_search · 1,940 ms
豆包搜索结果（原始查询:Bodycote Veritas Capital acquisition offer price per share cash terms 2026；API SearchType:web） - web_search 成功 doubao_search · 1,766 ms
豆包搜索结果（原始查询:Bodycote BOY.L ADR US listing tradable；API SearchType:web） - web_search 成功 doubao_search · 1,861 ms
豆包搜索结果（原始查询:Bodycote Veritas recommended cash offer 851 pence per share scheme September 2026；API SearchType:web）
原文全文
展开原文 · 1,964 字
SpaceX, Tesla shares rise after Musk says committees exploring possible merger
LONDON - Bodycote plc shareholders approved the recommended cash acquisition by Vulcan Alpha Bidco Limited, a company owned by funds managed by Veritas Capital Fund Management, according to a press release statement issued today.
At the Court Meeting held this morning, 99.79% of Scheme Shares voted were cast in favor of the acquisition, representing 72,373,141 shares. The resolution was supported by 196 shareholders, or 80.99% of those who voted. A total of 149,009 shares, representing 0.21% of votes cast, were against the proposal.
The special resolution at the General Meeting, held immediately after the Court Meeting, passed with 99.78% approval. A total of 72,339,259 Bodycote shares were voted in favor, while 159,546 shares were voted against.
The companies announced that the waiting period under the HSR Act for the acquisition has expired, satisfying one of the conditions outlined in the scheme document published on September 28, 2026. The boards of Bodycote and BidCo reached agreement on the acquisition terms on September 1, 2026.
The transaction remains subject to additional conditions, including merger control and foreign direct investment approvals in other jurisdictions, court sanction of the scheme, and delivery of the court order to the Registrar of Companies. Filing processes for regulatory approvals in other jurisdictions are progressing as expected.
The acquisition is expected to become effective in the first quarter of 2027. The transaction will be implemented through a court-sanctioned scheme of arrangement under Part 26 of the Companies Act.
Barclays and Goldman Sachs serve as joint lead financial advisers to Bodycote, with Jefferies and Perella Weinberg also advising. Lazard is acting as financial adviser to Veritas and BidCo.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LONDON - Bodycote plc shareholders approved the recommended cash acquisition by Vulcan Alpha Bidco Limited, a company owned by funds managed by Veritas Capital Fund Management, according to a press release statement issued today.
At the Court Meeting held this morning, 99.79% of Scheme Shares voted were cast in favor of the acquisition, representing 72,373,141 shares. The resolution was supported by 196 shareholders, or 80.99% of those who voted. A total of 149,009 shares, representing 0.21% of votes cast, were against the proposal.
The special resolution at the General Meeting, held immediately after the Court Meeting, passed with 99.78% approval. A total of 72,339,259 Bodycote shares were voted in favor, while 159,546 shares were voted against.
The companies announced that the waiting period under the HSR Act for the acquisition has expired, satisfying one of the conditions outlined in the scheme document published on September 28, 2026. The boards of Bodycote and BidCo reached agreement on the acquisition terms on September 1, 2026.
The transaction remains subject to additional conditions, including merger control and foreign direct investment approvals in other jurisdictions, court sanction of the scheme, and delivery of the court order to the Registrar of Companies. Filing processes for regulatory approvals in other jurisdictions are progressing as expected.
The acquisition is expected to become effective in the first quarter of 2027. The transaction will be implemented through a court-sanctioned scheme of arrangement under Part 26 of the Companies Act.
Barclays and Goldman Sachs serve as joint lead financial advisers to Bodycote, with Jefferies and Perella Weinberg also advising. Lazard is acting as financial adviser to Veritas and BidCo.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
5baf7bcfa8· 2026-10-21 19:45 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前